Reimagining RNA medicine

Mar 05, 2026

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Feb 26, 2026

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

Feb 02, 2026

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

Jan 12, 2026

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

Jan 05, 2026

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference